ATALLPA

ATALLPA ofrece a sus clientes una experiencia gastronómica saludable con diversidad de sabores peruanos, hechos en base de insumos peruanos acompañados de ensaladas frescas y nutritivas y tubérculos cocidos, pensando siempre en el cuidado la salud. La propuesta va dirigida a personas entre 18 a 55 años de NSE A y B, personas deportistas con hábitos alimenticios saludables y personas que cuidan su salud, con pocas opciones para degustar este plato tradicional y exquisito que optan por el consumo de alternativos como comidas naturistas o preparar sus propios alimentos. ATALLPA cuenta con un mercado nicho de clientes potenciales para lograr un crecimiento de ventas de 3% anual apoyado por el crecimiento del sector de pollo a la brasa que es el plato típico más consumido por los peruanos. Debido a la oportunidad de crecimiento del consumo de este plato, el crecimiento de estilo de vida saludable y la pandemia actual que atraviesa el país; las personas cuidan lo que consumen. Asimismo, las personas valoran más la calidad del producto y los altos estándares de atención respecto al cuidado de la salud por el temor a contraer el nuevo coronavirus COVID – 19. Se planifica poner en marcha el proyecto ATALLPA con una inversión de S/ 89,340.00, los cuales generan un retorno de rentabilidad financiera expresado en Valor Actual Neto de S/ 163, 695.00 y la inversión total se recupera en 1.8 años.ATALLPA offers to its customers a healthy gastronomic experience with a diversity of Peruvian flavors, made from Peruvian inputs accompanied by fresh and nutritious salads and cooked tubers, always thinking about health care. The proposal is aimed at people between 18 and 55 years of age from NSE A and B, sportspeople with healthy eating habits and people who take care of their health, with few options for tasting this traditional and exquisite dish who opt for the consumption of alternatives such as naturist meals or preparing their own food. ATALLPA has a niche market of potential customers to achieve a sales growth of 3% per year supported by the growth of the grilled chicken sector which is the typical dish most consumed by Peruvians. Seeing the opportunity for growth in the consumption of this dish, and considering the growth of healthy lifestyle; and in turn by the pandemic that we are going through, people worry about what they consume, valuing more the quality of the product and the high standards of care regarding health care for fear of contracting the new coronavirus COVID-19. The ATALLPA project is planned to be executed with an investment of S/ 89,340.00, which will generate a return of financial profitability expressed in Net Present Value of S/ 163,695.00 and the total investment will be recovered in 1.8 years.Trabajo de investigació

Contemporary use of cefazolin for MSSA infective endocarditis: analysis of a national prospective cohort

Objectives: This study aimed to assess the real use of cefazolin for methicillin-susceptible Staphylococcus aureus (MSSA) infective endocarditis (IE) in the Spanish National Endocarditis Database (GAMES) and to compare it with antistaphylococcal penicillin (ASP). Methods: Prospective cohort study with retrospective analysis of a cohort of MSSA IE treated with cloxacillin and/or cefazolin. Outcomes assessed were relapse; intra-hospital, overall, and endocarditis-related mortality; and adverse events. Risk of renal toxicity with each treatment was evaluated separately. Results: We included 631 IE episodes caused by MSSA treated with cloxacillin and/or cefazolin. Antibiotic treatment was cloxacillin, cefazolin, or both in 537 (85%), 57 (9%), and 37 (6%) episodes, respectively. Patients treated with cefazolin had significantly higher rates of comorbidities (median Charlson Index 7, P <0.01) and previous renal failure (57.9%, P <0.01). Patients treated with cloxacillin presented higher rates of septic shock (25%, P = 0.033) and new-onset or worsening renal failure (47.3%, P = 0.024) with significantly higher rates of in-hospital mortality (38.5%, P = 0.017). One-year IE-related mortality and rate of relapses were similar between treatment groups. None of the treatments were identified as risk or protective factors. Conclusion: Our results suggest that cefazolin is a valuable option for the treatment of MSSA IE, without differences in 1-year mortality or relapses compared with cloxacillin, and might be considered equally effective